RxDoctor Payments Data

David Robbins, MD

Urology · North Miami, FLNPI 1588848683

Payments from drug & device makers

$79,109in general payments, 2019–2025

Across 477 payments — averaging $165.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$73K
  • Johnson & Johnson$2K
  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$531
  • AbbVie$382
  • Pfizer$374
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$15,82520%
  • Speaking & faculty fees$53,11167%
  • Travel & lodging$1,4662%
  • Food & beverage$8,32811%
  • Education$3790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,109 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$119,639
Medicare patients
324
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate178$1,057,312
ErleadaApalutamide37$561,537
TrelstarTriptorelin Pamoate176$440,880
GemtesaVibegron171$158,379
MyrbetriqMirabegron177$128,721
EligardLeuprolide Acetate35$47,471
Estradiol92$5,256
Tamsulosin Hcl533$5,179
Finasteride294$3,819
Tadalafil65$3,661
Testosterone37$3,556
CefuroximeCefuroxime Axetil251$3,396
Testosterone Cypionate106$2,940
Bicalutamide90$2,314
Sildenafil Citrate174$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$382$1,057,312178 claims
Johnson & JohnsonErleada$1,696$561,53737 claims
Verity Pharmaceuticals Inc.Trelstar$232$440,880176 claims
Sumitomo Pharma America, Inc.Gemtesa$301$158,379171 claims
Astellas Pharma US IncMyrbetriq$1,177$128,721177 claims
Tolmar Pharmaceuticals, Inc.Eligard$323$47,47135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in North Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →